Douglas Lind

Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL.

Founded in 2005, GBP Capital is a venture capital firm located in Greenwich, Connecticut.

MabVax Therapeutics, Inc. developed and commercialized immunotherapeutics for the treatment of cancer. The company was founded in 2006 and is headquartered in San Diego, CA.

Spectral Image, Inc. developed imaging technology for biomedical use. The company was headquartered in Tampa, FL.

Flexible Stenting Solutions, Inc. manufactures and distributes medical devices. It develops third-generation flexible peripheral arterial, venous, neurovascular and biliary stents. The company was founded by Janet W. Burpee in 2006 and is headquartered in Eatontown, NJ.

Opus Bio, Inc. develops and manufactures lentiviral gene delivery technologies. Its Lentiviral vectors (LV), technology platform is used for delivery of genetic sequence information into cells to reprogram function and to treat epithelial cancers. The company was founded by Boro Dropulic in 2004 and is headquartered in Baltimore, MD.

Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry.

TMune Therapeutics, Inc. provides cancer treatment research and technology development services. It focuses on the development of T-cell therapies for the treatment of cancer and infectious diseases. The firm's proprietary cell activation technology is used and administered in patients, who are undergoing treatment for leukemia, lymphoma, and HIV. The company was founded by Louis P. Berneman in 2008 and is headquartered in Greenwich, CT.